Sarah Kathryn Rouan is Director at Viking Therapeutics, Inc. (VKTX). They have made 2 open-market trades across 2 companies since 2019, most recently 2026-01-02.
CIK 0001761366
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $35K since 2019, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VKTX | BUY | 2025-03-31 | 2025-04-08 | $24.15 | $30K | +20.8% | +41.9% | +40.1% |
| VKTX | SELL · 10b5-1 | 2024-10-25 | 2024-10-25 | $80.89 | $890K | -16.7% | -34.2% | -55.8% |
| VKTX | SELL · 10b5-1 | 2024-02-08 | 2024-02-08 | $28.05 | $701K | +19.8% | +116.0% | +172.1% |
| VKTX | SELL · 10b5-1 | 2024-01-19 | 2024-01-19 | $23.05 | $692K | +10.5% | +63.6% | +196.0% |
| NAVB | BUY | 2019-05-17 | 2019-05-21 | $1.46 | $5K | +21.1% | -50.0% | -64.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.